Vitamin D deficiency has been reported to be a prevalent contemporary health problem with consequences beyond abnormalities in bone, calcium, and phosphorus metabolism. A deficiency in vitamin D has been associated with certain cancers (breast, colon, prostate), autoimmune disorders, and cardiovascular disease. In addition, the mental health consequences of vitamin D deficiency are also becoming clearer. Insufficient vitamin D has been linked to depressive symptoms, cognitive impairment, and the development of schizophrenia. There is evidence that vitamin D deficiency is also related to medical problems such as obesity, diabetes mellitus, and hypertension, to which patients with psychiatric illnesses are particularly vulnerable.

While screening patients with psychiatric disorders for medical problems has been recognized as valuable, vitamin D sufficiency is not routinely included as part of the screening. However, there is evidence that such screening should be included. The prevalence of vitamin D deficiency among Scandinavian outpatients with psychiatric disorders has been reported to be 56% and 67%. Among 53 patients at a private clinic in Australia, 58% were vitamin D deficient. More alarming, Tiangga et al found that 100% of 17 hospitalized male psychiatric inpatients in London, England, were vitamin D deficient, while Cardinal and Gregory found deficiency in 83% of 12 hospitalized elderly psychiatric inpatients in Cambridge, United Kingdom. In all of these studies, deficiency was defined in the generally accepted manner as a serum 25-hydroxyvitamin D (25-[OH]D) level ≤ 20 ng/mL (50 nmol/L). All studies concluded with the recommendation that psychiatric patients, particularly hospitalized patients, should be screened for vitamin D deficiency.

This descriptive study looked at a large number of newly admitted psychiatric inpatients in an impoverished urban area in New York City to examine whether a high rate of vitamin D deficiency in psychiatric patients is also present in North America. The main objective was to quantify the prevalence of vitamin D deficiency in this group in order to guide the modification of health risk screening procedures. A secondary objective was to identify subgroups of patients in this population that are more vulnerable to vitamin D deficiency.

**METHOD**

**Setting**

The survey took place in a 135-bed psychiatric inpatient service that treats acutely ill adult patients and is part of a 363-bed general hospital. The hospital serves an impoverished urban population in New York City. Data were collected between September 2010 and the first 2 weeks of December 2010.

**Patients**

The patients were unselected consecutive cases, who were admitted to 3 of the 6 units of the psychiatric inpatient service. All patients were aged 18 years or older. Psychiatric diagnoses were established by attending psychiatrists as part of the routine assessment using criteria from the DSM-IV. All patients received a complete medical assessment at admission.

**Laboratory Analyses**

Serum 25-([OH])D was analyzed by high-performance liquid chromatography, tandem mass spectrometry (Quest Diagnostics, Teterboro, New Jersey).
25-(OH)D2 (from ergocalciferol) and 25-(OH)D3 (from cholecalciferol) were measured.

### Statistical Analyses
Patients with a serum 25-(OH)D level ≤ 20 ng/mL were classified as deficient. Statistical analysis was performed using SOFA Statistics version 1.1.0 (Paton-Simpson and Associates Ltd, Auckland, New Zealand, 2011). The significance level was .05, 2-sided. Group differences were analyzed using either the Student t test or analysis of variance. These tests are robust for deviations from normality. Correlations between continuous variables were analyzed using the Pearson test of linear correlation.

### Ethics
After previous random sampling suggested that vitamin D deficiency might be prevalent among our patients, a decision was made to assess vitamin D status on all admissions. This decision was made on clinical grounds and was independent of this study. This study is an examination of the results of that decision. As the review of the data did not interfere with patient care and personal health information was safeguarded, this study was deemed exempt from institutional review board approval. As is standard practice, all patients were orally informed about the testing for vitamin D status, and 1 (0.9%) with dystymic disorder. Other diagnoses were dementia (n=2, 1.9%) and impulse control disorder not otherwise specified (n=2, 1.9%). Six (5.6%) patients were taking oral vitamin D at the time of admission; they were included in the analysis.

### Medical Issues
Twenty-seven (25.2%) patients had Type 2 diabetes mellitus and 33 (30.8%) had hypertension. The mean ± SD body mass index (BMI) was 29.2 ± 7.3 kg/m²; 38 (35.5%) patients were classified as obese, with a BMI ≥ 30 kg/m². The mean ± SD glycosylated hemoglobin (hemoglobin A1c) level was 5.9% ± 1.2%.

### Serum 25-Hydroxyvitamin D Level
The mean ± SD serum 25-(OH)D level was 21.1 ± 10.4 ng/mL; the median was 19.0 ng/mL, with a range of 5.0 to 63.0. Fifty-six (52.3%) patients were classified as deficient. There was a statistically significant correlation between serum 25-(OH)D level and age (Pearson r = 0.31, df = 105, P = .001) but not between 25-(OH)D and BMI (Pearson r = −0.10, df = 105, P = .30) or hemoglobin A1c (Pearson r = −0.01, df = 90, P = .91). Table 1 shows that there were no statistically significant differences in 25-(OH)D levels when examining gender, race/ethnicity, major psychiatric diagnoses, and the presence or absence of Type 2 diabetes mellitus, hypertension, and obesity.

Twenty-nine patients (27.1%) had a detectable level of 25-(OH)D3 that is assumed to be from nutritional supplements rather than from sun exposure; the mean ± SD serum level was 2.82 ± 6.13 ng/mL. For 25-(OH)D3, the mean ± SD serum level was 18.25 ± 9.14 ng/mL. Patients who had detectable 25-(OH)D3 levels were significantly less likely to be deficient in vitamin D (X²(1) = 19.64, P < .0001) than those with nondetectable levels. Fifty-one (65.4%) patients without detectable 25-(OH)D2 levels were deficient compared to 5 (17.2%) patients who had detectable levels.

Table 2 shows serum 25-(OH)D levels among the age categories, which were also used in the study by Humble et al.
al. There was a statistically significant difference among the 3 age groups, with the youngest group having the lowest level. When the age groups were divided by gender, only the male patients had significantly different serum 25-(OH)D levels among them, with the youngest having the lowest levels. Pairwise comparisons of the age groups for male patients showed that the youngest group had significantly lower serum 25-(OH)D levels compared to both the middle ($t = 2.53$, $df = 51$, $P = .014$) and oldest ($t = 3.44$, $df = 44$, $P = .001$) age groups. The difference in levels between the middle and oldest age group in male patients was not significant ($t = -0.60$, $df = 39$, $P = .55$). There was also a statistically significant relationship between a patient’s age group and being classified as deficient in vitamin D ($\chi^2 = 8.11$, $P = .017$), with 71.4% (25/35) of the youngest age group being deficient, while the middle and oldest age groups had deficiency rates of 46.5% (20/43) and 37.9% (11/29), respectively. Again, this comparison was significant for male patients ($\chi^2 = 8.59$, $P = .014$) but not female patients ($\chi^2 = 0.14$, $P = .93$).

**DISCUSSION**

This is the first study looking at the prevalence of vitamin D deficiency among psychiatric patients in North America. The majority (52.3%) of our unselected sample of psychiatric inpatients was deficient in vitamin D. These results are similar to studies that have looked at psychiatric patients in northern Europe and Australia. Recently, the National Center for Health Statistics reported that the mean prevalence of 25-(OH)D levels ≤ 20 ng/mL in the US general population, aged 19 years and older, was 37.5%. The results from our study suggest that the level of deficiency, already high among North Americans, is even higher among patients with major psychiatric illness. Some experts in the field propose that the 25-(OH)D level must be greater than 30 ng/mL to be sufficient; with those criteria, 91 (85.0%) patients in our sample would be classified as deficient.

The majority of our patients had dark skin, which is considered a risk factor for vitamin D deficiency, as more sun exposure is needed to maintain adequate blood levels. Dealberto has hypothesized a connection between having dark skin, being an immigrant, and having a greater risk of schizophrenia. Vitamin D deficiency is thought to be an important part of this connection. Black patients did have the lowest levels of 25-(OH)D in our sample, but this difference was not statistically significant.

The amount of 25-(OH)D is related to sun exposure. Levels fluctuate during the year with the highest from the sunlight of summer. As there is a 1-month to 2-month lag between changes in sun exposure and 25-(OH)D level, the samples in our patients, which were collected in autumn, most likely represent 25-(OH)D levels near their annual peak.

Increased age has been linked to vitamin D deficiency. However, in our study, younger patients, particularly younger males, had significantly lower 25-(OH)D levels and a higher prevalence of being vitamin D deficient. Humble et al. found similar results. Our sample had a small number of younger female patients, so no valid comparison can be made between genders in the younger age group. We can only speculate as to why younger psychiatric patients are more likely to be deficient in vitamin D. Perhaps younger patients have a lifestyle that exposes them to less sunlight and a diet with less vitamin D content than older patients. Another possible explanation is that more younger patients may have been taking medications such as anticonvulsants, steroids, or highly active antiretroviral therapy that enhance the destruction of 25-(OH)D. However, since many of our patients reported that they had not taken medication consistently before being admitted to the hospital, we do not have adequate data to test this hypothesis.

The connections between vitamin D deficiency and obesity, hypertension, and type 2 diabetes mellitus are demonstrated in our patient population who had a high prevalence of these medical illnesses. Obesity is a risk factor for lower 25-(OH)D levels as well as for type 2 diabetes mellitus and hypertension; lower 25-(OH)D levels result in less insulin production and increased renin synthesis, which increases vulnerability to developing type 2 diabetes mellitus and hypertension. Renal damage from diabetes mellitus or hypertension can decrease synthesis of 1,25-dihydroxyvitamin D, the active metabolite of vitamin D. These relationships highlight the value of assessing vitamin D status when managing chronic health problems such as obesity, hypertension, and type 2 diabetes mellitus.

The single site of this study is a limitation to generalizing the results. Another limitation is that an adequate level of 25-(OH)D and the best means of assaying it have not been definitively established. While some experts recommend using a higher cutoff value to determine deficiency, others believe it should be lower. As a result, our rates of deficiency may be higher or lower depending on how deficiency is defined.

In conclusion, vitamin D deficiency was highly prevalent in our sample of psychiatric inpatients. These results are in agreement with other studies and support our decision to screen for vitamin D deficiency as a part of the health assessment of patients with major psychiatric illnesses. Since most patients are deficient in vitamin D, a cost-efficient alternative to screening may be to treat all patients with pharmacologic doses of vitamin D (50,000 IU of ergocalciferol). Pietras et al. looked at patients treated with ergocalciferol for up to 6 years and found it helpful in maintaining sufficient levels of 25-(OH)D without toxic
effects. Identifying and treating vitamin D deficiency may provide many benefits to our patients, including having a positive effect on the psychiatric illness itself. However, further studies are needed to validate the latter point.

Author affiliations: Department of Psychiatry, Woodhull Medical and Mental Health Center, New York University School of Medicine, Brooklyn, New York.

Potential conflicts of interest: None reported.

Funding/support: None reported.

REFERENCES